Seattle Genetics, Merck partner on 2 oncology drug programs September 14, 2020 -- Seattle Genetics and Merck will collaborate to develop and commercialize Seattle Genetics' ladiratuzumab vedotin, an antibody-drug conjugate. Separately, Seattle Genetics has granted Merck an exclusive license to commercialize a small-molecule drug for treatment of HER2-positive cancers.
Gilead Sciences to acquire Immunomedics for $21B September 14, 2020 -- Gilead Sciences will acquire Immunomedics for $88 per share in cash, a transaction that values Immunomedics at approximately $21 billion. The deal is anticipated to close during the fourth quarter of 2020.
Integral Molecular adds to its antibody discovery platform September 10, 2020 -- Integral Molecular has developed humanized chicken antibody technology and incorporated it into its MPS antibody discovery platform for multipass membrane proteins. The tech will allow for the isolation of fully humanized antibodies directly from immunized animals.
New AI-based company targets discovery of new protein-based therapeutics September 10, 2020 -- Flagship Pioneering has launched Generate Biomedicines, a new company that will use its machine learning-powered platform for the rapid discovery of new drugs across a range of modalities, including antibodies, peptides, enzymes, and cytokines, and entirely new protein-based therapeutics.